Su influencia a través del continuum de la salud | 14 OCT 18

Los efectos de la pérdida de masa muscular

Reseña de la importancia de la masa muscular escasa sobre la salud en pacientes hospitalizados, ambulatorios y en instituciones de cuidados prolongados y revisión de las publicaciones del año pasado sobre este tema.
4
24
Autor: Prado CM, Purcell SA, Alish C Annals of Medicine 12 Sep 2018
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

[1] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010; 39:412–423.

[2] Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014; 69:547–558.

[3] Aubrey J, Esfandiari N, Baracos VE, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol. 2014; 210:489–497.

[4] Cawthon PM. Assessment of lean mass and physical performance in sarcopenia. J Clin Densitom. 2015; 18:467–471.

[5] Heymsfield SB, Gonzalez MC, Lu J, et al. Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia. Proc Nutr Soc. 2015; 74:355–366.

[6] Prado CM, Pinto CM, Gonzalez MC, et al. Techniques for Assessment of Body Composition in Health. Scientific American Nutrition. Hamilton, Ontario, Canada: Decker Intellectual Properties; 2017.

[7] Koukourikos K, Tsaloglidou A, Kourkouta L. Muscle atrophy in intensive care unit patients. Acta Inform Med. 2014; 22:406–410.

[8] Agency for Healthcare Research and Quality. Inpatient vs. Outpatient Surgeries in U.S. Hospitals Rockville, MD, USA March 2015. [cited 2018 Aug 24]. Available from: www.hcup-us.ahrq.gov/reports/infographics/inpt_outpt.jsp.

[9] Bisgaard T, Kehlet H. Early oral feeding after elective abdominal surgery—what are the issues? Nutrition. 2002; 18:944–948.

[10] Gani F, Buettner S, Margonis GA, et al. Sarcopenia predicts costs among patients undergoing major abdominal operations. Surgery. 2016; 160:1162–1171.

[11] Englesbe MJ, Lee JS, He K, et al. Analytic morphomics, core muscle size, and surgical outcomes. Ann Surg. 2012; 256:255–261.

[12] Lieffers JR, Bathe OF, Fassbender K, et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012; 107:931–936.

[13] Joglekar S, Nau PN, Mezhir JJ. The impact of sarcopenia on survival and complications in surgical sncology: A review of the current literature. J Surg Oncol. 2015; 112:503–509.

[14] Friedman J, Lussiez A, Sullivan J, et al. Implications of sarcopenia in major surgery. Nutr Clin Pract. 2015; 30:175–179.

[15] Hale AL, Twomey K, Ewing JA, et al. Impact of sarcopenia on long-term mortality following endovascular aneurysm repair. Vasc Med. 2016; 21:217–222.

[16] Higashi T, Hayashi H, Taki K, et al. Sarcopenia, but not visceral fat amount, is a risk factor of postoperative complications after major hepatectomy. Int J Clin Oncol. 2016; 21:310–319.

[17] Lee S, Paik HC, Haam SJ, et al. Sarcopenia of thoracic muscle mass is not a risk factor for survival in lung transplant recipients. J Thorac Dis. 2016; 8:2011–2017.

[18] Fukushima H, Nakanishi Y, Kataoka M, et al. Postoperative changes in skeletal muscle mass predict survival of patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. Clin Genitourin Cancer. 2017;15:e229–e238.

[19] Hervochon R, Bobbio A, Guinet C, et al. Body mass index and total psoas area affect outcomes in patients undergoing pneumonectomy for cancer. Ann Thorac Surg. 2017; 103:287–295.

[20] Hirasawa Y, Nakashima J, Yunaiyama D, et al. Sarcopenia as a novel preoperative prognostic predictor for survival in patients with bladder cancer undergoing radical cystectomy. Ann Surg Oncol. 2016; 23:1048–1054.

[21] Huang DD, Chen XX, Chen XY, et al. Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: a prospective study. J Cancer Res Clin Oncol. 2016; 142: 2347–2356.

[22] Ishihara H, Kondo T, Omae K, et al. Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multiinstitution study. Int J Clin Oncol. 2017; 22:136–144.

[23] Itoh S, Yoshizumi T, Kimura K, et al. Effect of Sarcopenic Obesity on Outcomes of Living-Donor Liver Transplantation for Hepatocellular Carcinoma. Anticancer Res. 2016; 36:3029– 3034.

[24] Malietzis G, Currie AC, Athanasiou T, et al. Influence of body composition profile on outcomes following colorectal cancer surgery. Br J Surg. 2016; 103:572–580.

[25] Okumura S, Kaido T, Hamaguchi Y, et al. Impact of skeletal muscle mass, muscle quality, and visceral adiposity on outcomes following resection of intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2017; 24:1037–1045.

[26] Paireder M, Asari R, Kristo I, et al. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer. Eur J Surg Oncol. 2017; 43:478–484.

[27] Psutka SP, Boorjian SA, Moynagh MR, et al. Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer. J Urol. 2016; 195:270–276.

[28] Suzuki Y, Okamoto T, Fujishita T, et al. Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer. Lung Cancer. 2016; 101:92–97.

[29] van Dijk DP, Bakens MJ, Coolsen MM, et al. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017; 8:317–326.

[30] Drudi LM, Phung K, Ades M, et al. Psoas muscle area predicts all-cause mortality after endovascular and open aortic aneurysm repair. Eur J Vasc Endovasc Surg. 2016; 52:764–769.

[31] Mok M, Allende R, Leipsic J, et al. Prognostic value of fat mass and skeletal muscle mass determined by computed tomography in patients who underwent transcatheter aortic valve implantation. Am J Cardiol.2016; 117:828–833.

[32] Paknikar R, Friedman J, Cron D, et al. Psoas muscle size as a frailty measure for open and transcatheter aortic valve replacement. J Thorac Cardiovasc Surg. 2016; 151:745–750.

[33] Saji M, Lim DS, Ragosta M, et al. Usefulness of psoas muscle area to predict mortality in patients undergoing transcatheter aortic valve replacement. Am J Cardiol. 2016; 118:251–257.

[34] Bokshan SL, Han AL, DePasse JM, et al. Effect of sarcopenia on postoperative morbidity and mortality after thoracolumbar spine surgery. Orthopedics. 2016; 39:e1159–e1e64.

[35] Hamaguchi Y, Kaido T, Okumura S, et al. Impact of skeletal muscle mass index, intramuscular adipose tissue content, and visceral to subcutaneous adipose tissue area ratio on early mortality of living donor liver transplantation. Transplantation. 2017; 101:565.

[36] Izumi T, Watanabe J, Tohyama T, et al. Impact of psoas muscle index on short-term outcome after living donor liver transplantation. Turk J Gastroenterol. 2016; 27:382–388.

[37] Rutten IJ, Ubachs J, Kruitwagen RF, et al. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery. Eur J Surg Oncol. 2017; 43:717–724.

[38] Boer BC, de Graaff F, Brusse-Keizer M, et al. Skeletal muscle mass and quality as risk factors for postoperative outcome after open colon resection for cancer. Int J Colorectal Dis. 2016; 31:1117–1124.

[39] Peyton CC, Heavner MG, Rague JT, et al. Does sarcopenia impact complications and overall survival in patients undergoing radical nephrectomy for stage III and IV kidney cancer? J Endourol. 2016; 30:229–236.

[40] Van Rijssen LB, van Huijgevoort NC, Coelen RJ, et al. Skeletal muscle quality is associated with worse survival after pancreatoduodenectomy for periampullary, nonpancreatic cancer. Ann Surg Oncol. 2017;24:272–280.

[41] Grotenhuis BA, Shapiro J, van Adrichem S, et al. Sarcopenia/muscle mass is not a prognostic factor for short- and long-term outcome after esophagectomy for cancer. World J Surg. 2016;40:2698–2704.

[42] Heberton GA, Nassif M, Bierhals A, et al. Usefulness of psoas muscle area determined by computed tomography to predict mortality or prolonged length of hospital stay in patients undergoing left ventricular assist device implantation. Am J Cardiol. 2016;118:1363–1367.

[43] Chemama S, Bayar MA, Lanoy E, et al. Sarcopenia is associated with chemotherapy toxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol. 2016;23:3891–3898.

[44] Lou N, Chi CH, Chen XD, et al. Sarcopenia in overweight and obese patients is a predictive factor for postoperative complication in gastric cancer: a prospective study. Eur J Surg Oncol. 2017;43:188–195.

[45] Makiura D, Ono R, Inoue J, et al. Preoperative sarcopenia is a predictor of postoperative pulmonary complications in esophageal cancer following esophagectomy: a retrospective cohort study. J Geriatr Oncol. 2016;7:430–436.

[46] Nishigori T, Okabe H, Tanaka E, et al. Sarcopenia as a predictor of pulmonary complications after esophagectomy for thoracic esophageal cancer. J Surg Oncol. 2016;113:678–684.

[47] Wang SL, Zhuang CL, Huang DD, et al. Sarcopenia adversely impacts postoperative clinical outcomes following gastrectomy in patients with gastric cancer: a prospective study. Ann Surg Oncol. 2016;23:556–564.

[48] Lindqvist C, Majeed A, Wahlin S. Body composition assessed by dual-energy X-ray absorptiometry predicts early infectious complications after liver transplantation. J Hum Nutr Diet. 2017;30:284–291.

[49] Dahya V, Xiao J, Prado CM, et al. Computed tomography-derived skeletal muscle index: A novel predictor of frailty and hospital length of stay after transcatheter aortic valve replacement. Am Heart J. 2016;182:21–27.

[50] Garg L, Agrawal S, Pew T, et al. Psoas muscle area as a predictor of outcomes in transcatheter aortic valve implantation. Am J Cardiol. 2017;119:457–460.

[51] Fujikawa H, Araki T, Okita Y, et al. Impact of sarcopenia on surgical site infection after restorative proctocolectomy for ulcerative colitis. Surg Today. 2017;47:92–98.

[52] Nardelli S, Lattanzi B, Torrisi S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol. 2017;15:934–936.

[53] Nishida Y, Kato Y, Kudo M, et al. Preoperative sarcopenia strongly influences the risk of postoperative pancreatic fistula formation after pancreaticoduodenectomy. J Gastrointest Surg. 2016;20:1586–1594.

[54] Kalafateli M, Mantzoukis K, Choi Yau Y, et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the model for end-stage liver disease score. J Cachexia Sarcopenia Muscle. 2017;8:113–121.

[55] Tsaousi G, Kokkota S, Papakostas P, et al. Body composition analysis for discrimination of prolonged hospital stay in colorectal cancer surgery patients. Eur J Cancer Care. 2017;26:e12491.

[56] Onesti JK, Wright GP, Kenning SE, et al. Sarcopenia and survival in patients undergoing pancreatic resection. Pancreatol. 2016;16:284–289.

[57] Weig T, Milger K, Langhans B, et al. Core muscle size predicts postoperative outcome in lung transplant candidates. Ann Thorac Surg. 2016;101:1318–1325.

[58] Harada K, Ida S, Baba Y, et al. Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma. Dis Esophagus. 2016;29:627–633.

[59] Jo S, Park SB, Kim MJ, et al. Comparison of balance, proprioception and skeletal muscle mass in total hip replacement patients with and without fracture: a pilot study. Ann Rehabil Med. 2016;40:1064–1070.

[60] Reisinger KW, Derikx JP, van Vugt JL, et al. Sarcopenia is associated with an increased inflammatory response to surgery in colorectal cancer. Clin Nutr. 2016;35:924–927. [61] Sousa AS, Guerra RS, Fonseca I, et al. Financial impact of sarcopenia on hospitalization costs. Eur J Clin Nutr. 2016;70:1046–1051.

[62] van Vugt JLA, Buettner S, Levolger S, et al. Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract. PLoS One.2017;12:e0186547.

[63] Aahlin EK, Trano G, Johns N, et al. Health-related quality of life, cachexia and overall survival after major upper abdominal surgery: a prospective cohort study. Scand J Surg. 2017;106:40–46.

[64] Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30–41.

[65] Fulster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34:512–519.

[66] Uematsu M, Akashi YJ, Ashikaga K, et al. Association between heart rate at rest and myocardial perfusion in patients with acute myocardial infarction undergoing cardiac rehabilitation - a pilot study. Aoms.2012;4:622–630.

[67] Matsubara Y, Matsumoto T, Inoue K, et al. Sarcopenia is a risk factor for cardiovascular events experienced by patients with critical limb ischemia. J Vasc Surg. 2017;65:1390–1397.

[68] Bekfani T, Pellicori P, Morris DA, et al. Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. Int J Cardiol. 2016;222:41–46.

[69] Zuckerman J, Ades M, Mullie L, et al. Psoas muscle area and length of stay in older adults undergoing cardiac operations. Ann Thorac Surg. 2017;103:1498–1504.

[70] Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73:391–398.

[71] Isoyama N, Qureshi AR, Avesani CM, et al. Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin J Am Soc Nephrol. 2014;9:1720–1728.

[72] Hsiao SM, Tsai YC, Chen HM, et al. Association of fluid status and body composition with physical function in patients with chronic kidney disease. PLoS One. 2016;11:e0165400.

[73] Segura-Orti E, Gordon PL, Doyle JW, et al. Correlates of physical functioning and performance across the spectrum of kidney function. Clin Nurs Res. 2018;27:579–596.

[74] Barros A, Costa BE, Mottin CC, et al. Depression, quality of life, and body composition in patients with end-stage renal disease: a cohort study. Ver Bras Psiquiatr. 2016;38:301–306.

[75] Locke JE, Carr JJ, Nair S, et al. Abdominal lean muscle is associated with lower mortality among kidney waitlist candidates. Clin Transplant. 2017;31:e12911.

[76] Malhotra R, Deger SM, Salat H, et al. Sarcopenic obesity definitions by body composition and mortality in the hemodialysis patients. J Ren Nutr. 2017;27:84–90.

[77] Schols AM, Ferreira IM, Franssen FM, et al. Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respir J. 2014;44:1504–1520.

[78] Slinde F, EllegÅRd L, Gr€ONberg AM, et al. Total energy expenditure in underweight patients with severe chronic obstructive pulmonary disease living at home. Clin Nutr. 2003;22:159–165.

[79] Baarends EM, Schols AM, Westerterp KR, et al. Total daily energy expenditure relative to resting energy expenditure in clinically stable patients with COPD. Thorax. 1997;52:780–785.

[80] Vestbo J, Prescott E, Almdal T, et al. Body mass, fatfree body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med. 2006;173:79–83.

[81] Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis.1993;147:1151–1156.

[82] Joppa P, Tkacova R, Franssen FM, et al. Sarcopenic obesity, functional outcomes, and systemic inflammation in patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2016;17:712–718.

[83] Pothirat C, Chaiwong W, Phetsuk N, et al. The relationship between body composition and clinical parameters in chronic obstructive pulmonary disease. J Med Assoc Thai. 2016;99:386–393.

[84] Hwang JA, Kim YS, Leem AY, et al. Clinical implications of sarcopenia on decreased bone density in men with COPD. Chest. 2017;151:1018–1027.

[85] Society of Critical Care Medicine. Critical Care Patients. Mount Prospect, IL; 2016 [cited 2018 Aug 24].

[86] Preiser J-C, van Zanten ARH, Berger MM, et al. Metabolic and nutritional support of critically ill patients: consensus and controversies. Crit Care. 2015;19:35.

[87] Weijs PJ, Looijaard WG, Dekker IM, et al. Low skeletal muscle area is a risk factor for mortality in mechanically ventilated critically ill patients. Crit Care.2014;18:R12.

[88] Moisey LL, Mourtzakis M, Cotton BA, et al. Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. Crit Care. 2013;17:R206.

[89] McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: society of critical care medicine (SCCM) and American society for parenteral and enteral nutrition (A.S.P.E.N.). Jpen J Parenter Enteral Nutr. 2016;40: 159–211.

[90] Akahoshi T, Yasuda M, Momii K, et al. Sarcopenia is a predictive factor for prolonged intensive care unit stays in high-energy blunt trauma patients. Acute Med Surg. 2016;3:326–331.

[91] Thibault R, Makhlouf AM, Mulliez A, et al. Fat-free mass at admission predicts 28-day mortality in intensive care unit patients: the international prospective observational study phase angle project. Intensive Care Med. 2016;42:1445–1453.

[92] Dirks RC, Edwards BL, Tong E, et al. Sarcopenia in emergency abdominal surgery. J Surg Res. 2017;207:13–21.

[93] Leeper CM, Lin E, Hoffman M, et al. Computed tomography abbreviated assessment of sarcopenia following trauma: the CAAST measurement predicts 6-month mortality in older adult trauma patients. J Trauma Acute Care Surg. 2016;80:805–811.

[94] Looijaard WG, Dekker IM, Stapel SN, et al. Skeletal muscle quality as assessed by CT-derived skeletal muscle density is associated with 6-month mortality in mechanically ventilated critically ill patients. Crit Care. 2016;20:386.

[95] Shibahashi K, Sugiyama K, Kashiura M, et al. Decreasing skeletal muscle as a risk factor for mortality in elderly patients with sepsis: a retrospective cohort study. J Intensive Care. 2017;5:8

[96] Wallace JD, Calvo RY, Lewis PR, et al. Sarcopenia as a predictor of mortality in elderly blunt trauma patients: Comparing the masseter to the psoas using computed tomography. J Trauma Acute Care Surg. 2017;82:65–72.

[97] Rutten IJG, Ubachs J, Kruitwagen RFPM, et al. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle. 2017;8:630–638.

[98] Sousa AS, Guerra RS, Fonseca I, et al. Sarcopenia and length of hospital stay. Eur J Clin Nutr. 2016;70:595–601.

[99] Shintakuya R, Uemura K, Murakami Y, et al. Sarcopenia is closely associated with pancreatic exocrine insufficiency in patients with pancreatic disease. Pancreatology. 2017;17:70–75.

[100] Maeda K, Akagi J. Sarcopenia is an independent risk factor of dysphagia in hospitalized older people. Geriatr Gerontol Int. 2016;16:515–521.

[101] Maeda K, Takaki M, Akagi J. Decreased skeletal muscle mass and risk factors of sarcopenic dysphagia: A prospective observational cohort study. J Gerontol A Biol Sci Med Sci. 2016;72:1290–1294.

[102] Rinaldi JM, Geletzke AK, Phillips BE, et al. Sarcopenia and sarcopenic obesity in patients with complex abdominal wall hernias. Am J Surg. 2016;212:903–911.

[103] Maeda K, Akagi J. Muscle mass loss is a potential predictor of 90-day mortality in older adults with aspiration pneumonia. J Am Geriatr Soc. 2017;65:e18–e22.

[104] Perez-Zepeda MU, Sgaravatti A, Dent E. Sarcopenia and post-hospital outcomes in older adults: a longitudinal study. Arch Gerontol Geriatr. 2017;69:105–109.

[105] Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10:90–99.

[106] Purcell SA, Elliott SA, Baracos VE, et al. Key determinants of energy expenditure in cancer and implications for clinical practice. Eur J Clin Nutr. 2016;70:1230–1238.

[107] Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–635.

[108] Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013;21:1569–1577.

[109] Prado CMM, Mourtzakis M, Baracos V, et al. Overweight and obese patients with solid tumors may have sarcopenia, poor prognosis and early features of cachexia. Int J Body Compos Res. 2010;8:7–15.

[110] Prado CM, Cushen SJ, Orsso CE, et al. Sarcopenia and cachexia in the era of obesity: clinical and nutritional Impact. Proc Nutr Soc. 2016;75:188–198.

[111] Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004;97:2333–2338.

[112] Xiao J, Caan BJ, Weltzien E, et al. Associations of pre-existing co-morbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer. J Cachexia Sarcopenia Muscle. 2018;9:654–663.

[113] Daly L, Prado CM, Ryan A. A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes. Proc Nutr Soc. 2018;77:135–151.

[114] Zhuang CL, Huang DD, Pang WY, et al. Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a largescale cohort. Medicine (Baltimore). 2016;95:e3164.

[115] Begini P, Gigante E, Antonelli G, et al. Sarcopenia predicts reduced survival in patients with hepatocellular carcinoma at first diagnosis. Ann Hepatol. 2017;16:107–114.

[116] Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol 2016;34:1339–1344.

[117] Chu MP, Lieffers J, Ghosh S, et al. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximabbased chemoimmunotherapy. J Cachexia Sarcopenia Muscle. 2017;8:298–304.

[118] Daly LE, Power DG, O’Reilly A, et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017;116:310–317.

[119] Fukushima H, Nakanishi Y, Kataoka M, et al. Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma. J Urol. 2016; 195:26–32.

[120] Giap F, Lau SKM, Gannavarapu BS, et al. Impact of cachexia at diagnosis on radiotherapy utilization and survival in non-small cell lung cancer. Jco. 2016;34:133.

[121] Hiraoka A, Hirooka M, Koizumi Y, et al. Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2017;47:558–565.

[122] Ishihara H, Kondo T, Omae K, et al. Sarcopenia and the modified glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment. Targ Oncol. 2016;11:605–617.

[123] Kamachi S, Mizuta T, Otsuka T, et al. Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. Hepatol Res. 2016;46:201–208.

[124] Liu J, Motoyama S, Sato Y, et al. Decreased skeletal muscle mass after neoadjuvant therapy correlates with poor prognosis in patients with esophageal cancer. Ar. 2016;36:6677–6685.

[125] Malietzis G, Johns N, Al-Hassi HO, et al. Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer. Ann Surg. 2016;263:320–325.

[126] Rollins KE, Tewari N, Ackner A, et al. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr. 2016;35:1103–1109.

[127] Taguchi S, Akamatsu N, Nakagawa T, et al. Sarcopenia evaluated using the skeletal muscle index is a significant prognostic factor for metastatic urothelial carcinoma. Clin Genitourin Cancer. 2016;14:237–243.

[128] Kumar A, Moynagh MR, Multinu F, et al. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol. 2016;142:311–316.

[129] Rier HN, Jager A, Sleijfer S, et al. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast. 2017;31:9–15.

[130] Sjoblom B, Gronberg BH, Wentzel-Larsen T, et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clin Nutr. 2016;35:1386–1393.

[131] Veld J, Vossen JA, De Amorim Bernstein K, et al. Adipose tissue and muscle attenuation as novel biomarkers predicting mortality in patients with extremity sarcomas. Eur Radiol. 2016;26:4649–4655.

[132] Go SI, Park MJ, Song HN, et al. Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer. Support Care Cancer. 2016;24:2075–2084.

[133] Ninomiya G, Fujii T, Yamada S, et al. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: a retrospective cohort study. Int J Surg. 2017;39:45–51.

[134] Xiao DY, Luo S, O’Brian K, et al. Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Am J Hematol. 2016;91:1002–1007.

[135] Srdic D, Plestina S, Sverko-Peternac A, et al. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancerchemotherapy toxicity and prognostic value. Support Care Cancer. 2016;24:4495–4502.

[136] Shachar SS, Deal AM, Weinberg M, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res. 2017;23:658–665.

[137] Owen OE, Trapp VE, Reichard GA, Jr, et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J Clin Invest. 1983;72:1821–1832.

[138] Montano-Loza AJ, Angulo P, Meza-Junco J, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7:126–135.

[139] Hara N, Iwasa M, Sugimoto R, et al. Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis. Intern Med. 2016;55:863–870.

[140] Itoh S, Shirabe K, Yoshizumi T, et al. Skeletal muscle mass assessed by computed tomography correlates to muscle strength and physical performance at a liver-related hospital experience. Hepatol Res. 2016;46:292–297.

[141] Hanai T, Shiraki M, Ohnishi S, et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol Res. 2016;46:743–751.

[142] Nishikawa H, Enomoto H, Ishii A, et al. Prognostic significance of low skeletal muscle mass compared with protein-energy malnutrition in liver cirrhosis. Hepatol Res. 2017;47:1042–1052.

[143] Prado CM, Siervo M, Mire E, et al. A populationbased approach to define body-composition phenotypes. Am J Clin Nutr. 2014;99:1369–1377.

[144] Batsis JA, Mackenzie TA, Barre LK, et al. Sarcopenia, sarcopenic obesity and mortality in older adults:results from the National Health and Nutrition Examination Survey III. Eur J Clin Nutr. 2014;68:1001–1007.

[145] Rantanen T, Guralnik JM, Foley D, et al. Midlife hand grip strength as a predictor of old age disability. JAMA. 1999;281:558–560.

[146] Cesari M, Pahor M, Lauretani F, et al. Skeletal muscle and mortality: results from the InCHIANTI study. J Gerontol A-Biol. 2009;64A:377–384.

[147] Manini TM, Clark BC. Dynapenia and aging: an update. J Gerontol A Biol Sci Med Sci. 2012;67:28–40.

[148] Schaap LA, Koster A, Visser M. Adiposity, muscle mass, and muscle strength in relation to functional decline in older persons. Epidemiol Rev. 2013;35:51–65.

[149] Bouchi R, Fukuda T, Takeuchi T, et al. Sarcopenia is associated with incident albuminuria in patients with type 2 diabetes: a retrospective observational study. J Diabetes Investig. 2017;8:783–787.

[150] Anderson DE, Quinn E, Parker E, et al. Associations of computed tomography-based trunk muscle size and density with balance and falls in older adults. J Gerontol A Biol Sci Med Sci. 2016;71:811–816.

[151] Bai HJ, Sun JQ, Chen M, et al. Age-related decline in skeletal muscle mass and function among elderly men and women in Shanghai, China: a cross sectional study. Asia Pac J Clin Nutr. 2016;25:326–332.

[152] Chang JS, Kim TH, Kim H, et al. Qualitative muscle mass index as a predictor of skeletal muscle function deficit in Asian older adults. Geriatr Gerontol Int. 2017;17:99–107.

[153] Han DS, Chang KV, Li CM, et al. Skeletal muscle mass adjusted by height correlated better with muscular functions than that adjusted by body weight in defining sarcopenia. Sci Rep. 2016;6:19457.

[154] Nishiyama O, Yamazaki R, Sano H, et al. Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis. Respirology. 2017;22:480–485.

[155] Orsatti FL, Nunes PR, Souza AP, et al. Predicting functional capacity from measures of muscle mass in postmenopausal women. Pm R. 2017;9:596–602.

[156] Schweitzer L, Geisler C, Johannsen M, et al. Associations between body composition, physical capabilities and pulmonary function in healthy older adults. Eur J Clin Nutr. 2017;71:389–394.

[157] Silva Neto LS, Karnikowski MG, Osorio NB, et al. Association between sarcopenia and quality of life in quilombola elderly in Brazil. Int J Gen Med. 2016;9:89–97.

[158] Tramontano A, Veronese N, Sergi G, et al. Prevalence of sarcopenia and associated factors in the healthy older adults of the Peruvian Andes. Arch Gerontol Geriatr. 2017;68:49–54.

[159] Trombetti A, Reid KF, Hars M, et al. Age-associated declines in muscle mass, strength, power, and physical performance: impact on fear of falling and quality of life. Osteoporos Int. 2016;27:463–471.

[160] Graf CE, Herrmann FR, Spoerri A, et al. Impact of body composition changes on risk of all-cause mortality in older adults. Clin Nutr. 2016;35:1499–1505.

[161] Wu TY, Liaw CK, Chen FC, et al. Sarcopenia screened with SARC-F questionnaire is associated with quality of life and 4-year mortality. J Am Med Dir Assoc. 2016;17:1129–1135.

[162] Zhao Q, Zmuda JM, Kuipers AL, et al. Greater skeletal muscle fat infiltration is associated with higher allcause mortality among men of African ancestry. Age Ageing. 2016;45:529–534.

[163] Rodriguez AJ, Scott D, Khan B, et al. Low relative lean mass is associated with increased likelihood of abdominal aortic calcification in community-dwelling older Australians. Calcif Tissue Int. 2016;99:340–349.

[164] El Maghraoui A, Ebo’o FB, Sadni S, et al. Is there a relation between pre-sarcopenia, sarcopenia, cachexia and osteoporosis in patients with ankylosing spondylitis? BMC Musculoskelet Disord. 2016;17:268.

[165] Hida T, Shimokata H, Sakai Y, et al. Sarcopenia and sarcopenic leg as potential risk factors for acute osteoporotic vertebral fracture among older women. Eur Spine J. 2016;25:3424–3431.

[166] Inomoto A, Fukuda R, Deguchi Phn J, et al. The association between the body composition and lifestyle affecting pulmonary function in Japanese workers. J Phys Ther Sci. 2016;28:2883–2889.

[167] Yang R, Zhang Y, Shen X, et al. Sarcopenia associated with renal function in the patients with type 2 diabetes. Diabetes Res Clin Pract. 2016;118:121–129.

[168] Haider S, Luger E, Kapan A, et al. Associations between daily physical activity, handgrip strength, muscle mass, physical performance and quality of life in prefrail and frail community-dwelling older adults. Qual Life Res. 2016;25:3129–3138.

[169] Visser M, Deeg DJ, Lips P, et al. Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women. J Am Geriatr Soc. 2000;48:381–386.

[170] McGregor RA, Cameron-Smith D, Poppitt SD. It is not just muscle mass: a review of muscle quality, composition and metabolism during ageing as determinants of muscle function and mobility in later life. Longev Healthspan 2014;3:9.

[171] Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61:1059–1064.

[172] Brown JC, Harhay MO, Harhay MN. Sarcopenia and mortality among a population-based sample of community-dwelling older adults. J Cachexia Sarcopenia Muscle. 2016;7:290–298.

[173] Chuang SY, Hsu YY, Chen RC, et al. Abdominal obesity and low skeletal muscle mass jointly predict total mortality and cardiovascular mortality in an elderly Asian population. J Gerontol A Biol Sci Med Sci. 2016;71:1049–1055.

[174] Pasco JA, Mohebbi M, Holloway KL, et al. Musculoskeletal decline and mortality: prospective data from the Geelong Osteoporosis Study. J Cachexia Sarcopenia Muscle. 2017;8:482–489.

[175] Reinders I, Murphy RA, Brouwer IA, et al. Muscle quality and myosteatosis: novel associations with mortality risk: the age, gene/environment susceptibility (AGES)-reykjavik study. Am J Epidemiol. 2016;183:53–60.

[176] Spahillari A, Mukamal KJ, DeFilippi C, et al. The association of lean and fat mass with all-cause mortality in older adults: The Cardiovascular Health Study. Nutr Metab Cardiovasc Dis. 2016;26:1039–1047.

[177] Srikanthan P, Horwich TB, Tseng CH. Relation of muscle mass and fat mass to cardiovascular disease mortality. Am J Cardiol. 2016;117:1355–1360.

[178] Scott D, Seibel M, Cumming R, et al. Sarcopenic obesity and its temporal associations with changes in bone mineral density, incident falls, and fractures in older men: the concord health and ageing in men project. J Bone Miner Res. 2017;32:575–583.

[179] He H, Liu Y, Tian Q, et al. Relationship of sarcopenia and body composition with osteoporosis. Osteoporos Int. 2016;27:473–482.

[180] Oliveira PD, Wehrmeister FC, Perez-Padilla R, et al. Relationship between body composition and pulmonary function in early adult life: a cross-sectional analysis nested in two birth cohort studies. PLoS One. 2016;11:e0163428.

[181] Hirani V, Naganathan V, Blyth F, et al. Longitudinal associations between body composition, sarcopenic obesity and outcomes of frailty, disability, institutionalization and mortality in community-dwelling older men: the concord health and ageing in men project. Age Ageing. 2017;46:413–420.

[182] Hars M, Biver E, Chevalley T, et al. Low lean mass predicts incident fractures independently from frax: a prospective cohort study of recent retirees. J Bone Miner Res. 2016;31:2048–2056.

[183] Sornay-Rendu E, Duboeuf F, Boutroy S, et al. Muscle mass is associated with incident fracture in postmenopausal women: The OFELY study. Bone. 2017;94:108–113.

[184] An KO, Kim J. Association of sarcopenia and obesity with multimorbidity in korean adults: a nationwide cross-sectional study. J Am Med Dir Assoc. 2016;17:960 e1–967.

[185] Cawthon PM, Lui LY, McCulloch CE, et al. Sarcopenia and health care utilization in older women. J Gerontol A Biol Sci Med Sci. 2017;72:95–101.

[186] Bauer JM, Kaiser MJ, Sieber CC. Sarcopenia in nursing home residents. J Am Med Dir Assoc. 2008;9:545–551.

[187] Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing. 2014;43:748–759.

[188] Landi F, Liperoti R, Fusco D, et al. Sarcopenia and mortality among older nursing home residents. J Am Med Dir Assoc. 2012;13:121–126. [189] Huang CY, Hwang AC, Liu LK, et al. Association of dynapenia, sarcopenia, and cognitive impairment among community-dwelling older Taiwanese. Rejuvenation Res. 2016;19:71–78.

[190] Moon JH, Moon JH, Kim KM, et al. Sarcopenia as a predictor of future cognitive impairment in older adults. J Nutr Health Aging. 2016;20:496–502.

[191] Yamanouchi A, Yoshimura Y, Matsumoto Y, et al. Severely decreased muscle mass among older patients hospitalized in a long-term care ward in Japan. J Nutr Sci Vitaminol (Tokyo). 2016;62:229–234.

[192] Sugimoto T, Ono R, Murata S, et al. Sarcopenia is associated with impairment of activities of daily living in Japanese patients with early-stage Alzheimer disease. Alzheimer Dis Assoc Disord. 2017;31:256–258.

[193] Tufan A, Bahat G, Ozkaya H, et al. Low skeletal muscle mass index is associated with function and nutritional status in residents in a Turkish nursing home. Aging Male. 2016;19:182–186.

[194] Takagi D, Hirano H, Watanabe Y, et al. Relationship between skeletal muscle mass and swallowing function in patients with Alzheimer’s disease. Geriatr Gerontol Int. 2016;17:402–409.

[195] Yalcin A, Aras S, Atmis V, et al. Sarcopenia and mortality in older people living in a nursing home in Turkey. Geriatr Gerontol Int. 2017;17:1118–1124.

[196] Janssen I, Shepard DS, Katzmarzyk PT, et al. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52:80–85.

[197] Du K, Goates S, Arensberg MB, et al. Impact of sarcopenia on falls and hospitalization in community dwelling adults. J Frailty Aging. 2017;6(S1):165.

[198] Goates S, Du K, Arensberg M, et al. Cost burden of sarcopenia associated hospitalization in adults by age and race/ethnicity. ISPOR 22nd Annual International Meeting. Boston, MA; 2017.

[199] Yoshimura Y, Wakabayashi H, Yamada M, et al. Interventions for treating sarcopenia: a systematic review and meta-analysis of randomized controlled studies. J Am Med Dir Assoc. 2017;18:553 e1–e16.

[200] Deutz NE, Safar A, Schutzler S, et al. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr. 2011;30:759–768.

[201] Engelen MP, Safar AM, Bartter T, et al. High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer. Ann Oncol. 2015;26:1960–1966.

[202] Engelen M, Klimberg VS, Allasia A, et al. Presence of early stage cancer does not impair the early protein metabolic response to major surgery. J Cachexia Sarcopenia Muscle. 2017;8:447–456.

[203] Jonker R, Deutz NE, Erbland ML, et al. Effectiveness of essential amino acid supplementation in stimulating whole body net protein anabolism is comparable between COPD patients and healthy older adults. Metabolism. 2017;69:120–129.

[204] Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14:531–532.

[205] Malmstrom TK, Miller DK, Simonsick EM, et al. SARCF: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7:28–36.

[206] Earthman CP. Body composition tools for assessment of adult malnutrition at the bedside: a tutorial on research considerations and clinical applications. JPEN J Parenter Enteral Nutr. 2015;39:787–822.

[207] Sallinen J, Stenholm S, Rantanen T, et al. Hand-Grip Strength cut points to screen older persons at risk for mobility limitation. J Am Geriatr Soc. 2010;58:1721–1726.

[208] Mauricio SF, Xiao J, Prado CM, et al. Different nutritional assessment tools as predictors of postoperative complications in patients undergoing colorectal cancer resection. Clin Nutr. 2017. DOI:10.1016/j.clnu.2017.08.026

[209] Fearon KCH, Argiles JM, Baracos VE, et al. Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle. 2015;6:272–274.

[210] Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.

[211] Laban MM. Atrophy and clinical weakness of the iliopsoas muscle: a manifestation of hip osteoarthritis. Am J Phys Med Rehabil. 2006;85:629.

[212] Cooper RG, Forbes WSC, Jayson MIV. Radiographic demonstration of paraspinal muscle wasting in patients with chronic low back pain. Rheumatology. 1992;31:389–394.

[213] Avrutin E, Moisey LL, Zhang R, et al. Clinically practical approach for screening of low muscularity using electronic linear measures on computed tomography images in critically ill patients. JPEN J Parenter Enteral Nutr. 2018;42:885–891.

[214] Baracos VE. Psoas as a sentinel muscle for sarcopenia: a flawed premise. J Cachexia Sarcopenia Muscle. 2017;8:527–528.

[215] Abe T, Kawakami Y, Suzuki Y, et al. Effects of 20 days bed rest on muscle morphology. J Gravit Physiol. 1997;4:S10–S14.

[216] Brewster DJ, Strauss BJ, Crozier TM. Measuring visceral fat, subcutaneous fat and skeletal muscle area changes by computed tomography in acute pancreatitis: a retrospective, single-centre study. Crit Care Resusc. 2014;16:42–47.

[217] Paris M, Mourtzakis M. Assessment of skeletal muscle mass in critically ill patients: considerations for the utility of computed tomography imaging and ultrasonography. Curr Opin Clin Nutr Metab Care. 2016;19:125–130.

[218] Beaudart C, Dawson A, Shaw SC, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int. 2017;28:1817–1833.

[219] ClinicalTrials.gov. Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy (MENAC). NCT02330926 January 2017 [cited 2018 Aug 24].

[220] Clinicaltrials.gov. NCT03021902: Nutrition and Exercise in Critical Illness (NEXIS). Bethesda, MD;2017 [cited 2018 Aug 24].

[221] Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. Jco. 2013;31:1539–1547.

[222] Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755–763.

[223] Delmonico MJ, Harris TB, Lee J-S, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc. 2007;55:769–774.

[224] Newman AB, Kupelian V, Visser M, et al. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc. 2003;51:1602–1609.

[225] Chien MY, Huang TY, Wu YT. Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan. J Am Geriatr Soc. 2008;56:1710–1715.

[226] Janssen I, Baumgartner RN, Ross R, et al. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol. 2004;159:413–421.

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí